1. Wolff-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289 (18): 2363–9.
2. Whitworth JA and World Health Organization, International Society of Hypertension Writing Group. World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21 (11): 1983–92.
3. Grassi G, Cifkova R, Laurent S et al. Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. Eur Heart J 2011; 32: 218–25.
4. Kotsevaa K, Wooda D, De Backerb G et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16 (2): 121–37.
5. Graettinger WF2003 Systemic Hypertension. In: Crawford MH (eds). Current Diagnosis and Treatment in Cardiology 2nd edn. MacGraw-Hill Professional: New York, NY, USA; p. 167–78.
6. Appel GB, Appel AS. Angiotensin II receptor antagonists: role in hypertension, cardiovascular disease, and renoprotection. Prog Cardiovasc Dis 2004; 47 (2): 105–15.
7. Messerli FH, Weber MA, Brunner HR. Angiotensin II receptor inhibition, a new therapeutic principle. Arch Intern Med 1996; 156 (17): 1957–65.
8. Perry CM. Azilsartan medoxomil: a review of its use in hypertension. Clin Drug Investig 2012; 32 (9): 621–39.
9. Ojima M, Igata H, Tanaka M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336 (3): 801–8.
10. Bönner G, Bakris GL, Sica D et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens 2013; 27 (8): 479–86.
11. Sica D, White WB, Weber MA et al. Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring. J Clin Hypertens 2011; 13: 467–72.
12. White WB, Weber MA, Sica D et al. Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension. Hypertension 2011; 57: 413–20.
13. Metoki H, Ohkubo T, Kikuya M et al. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: The Ohasama study. Hypertension 2006; 47: 149–54.
14. Kikuya M, Ohkubo T, Asayama K et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: The Ohasama study. Hypertension 2005; 45: 240–5.
15. Hoshide S, Kario K, Hoshide Y et al. Associations between nondipping of nocturnal blood pressure decrease and cardiovascular target organ damage in strictly selected community-dwelling normotensives. Am J Hypertens 2003; 16: 434–8.
16. Ohkubo T, Imai Y, Tsuji I et al. Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. Am J Hypertens 1997; 10: 1201–7.
17. Kario K, Matsuno T, Kobayashi H et al. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996; 27: 130–5.
18. Kario K, Pickering TG, Matsuo T et al. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 2001; 38: 852–7.
19. Ohkubo T, Hozawa A, Yamaguchi J et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: The Ohasama study. J Hypertens 2002; 20: 2183–9.
20. Rakugi H, Kario К, Enya К et al. Effect of azilsartan versus candesartan on nocturnal blood pressure variation in Japanese patients with essential hypertension. Blood Press 2013; 22 (S1): 22–8.
21. Uzu T, Kimura G. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 1999; 100: 1635–8.
22. Sherwood A, Steffen PR, Blumenthal JA et al. Night-time blood pressure dipping: The role of the sympathetic nervous system. Am J Hypertens 2002; 15: 111–8.
23. Grassi G, Seravalle G, Quarti-Trevano F et al. Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension 2008; 52: 925–31.
24. Kario K, Schwartz JE, Pickering TG. Changes of nocturnal blood pressure dipping status in hypertensives by night-time dosing of α-adrenergic blocker, doxazosin: Results from the HALT study. Hypertension 2000; 35: 787–94.
25. Anan F, Takahashi N, Ooie T et al. Role of insulin resistance in nondipper essential hypertensive patients. Hypertens Res 2003; 26: 669–76.
26. Della Mea P, Lupia M, Bandolin V et al. Adiponectin, insulin resistance, and left ventricular structure in dipper and nondipper essential hypertensive patients. Am J Hypertens 2005; 18: 30–5.
27. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006; 24 (1): 11–25.
28. Sodhi CP, Kanwar YS, Sahai A. Hypoxia and high glucose upregulate AT1 receptor expression and potentiate ANG II-induced proliferation in VSM cells. Am J Physiol Heart Circ Physiol 2003; 284 (3): H846–H852.
29. Arun KH, Kaul CL, Ramarao P. AT1 receptors and L-type calcium channels: functional coupling in supersensitivity to angiotensin II in diabetic rats. Cardiovasc Res 2005; 65 (2): 374–86.
30. Sueta D, Kataoka К, Koibuchi N et al. Novel Mechanism for Disrupted Circadian Blood Pressure Rhythm in a Rat Model of Metabolic Syndrome – The Critical Role of Angiotensin II. Hypertension 2013; 2: e000035.

И.И.Чукаева, Ф.Д.Ахматова

ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва

________________________________________________

I.I.Chukaeva, F.D.Ahmatova